公开(公告)号：US07276342B2

公开(公告)日：2007-10-02

申请号：US10485233

申请日：2002-07-31

申请人： John Lucas ,  Deno P. Dialynas ,  Kristen Briggs

发明人： John Lucas ,  Deno P. Dialynas ,  Kristen Briggs

IPC分类号： G01N33/53 ,  C07K14/00 ,  A61K38/00

CPC分类号： G01N33/6863 ,  A61K38/177 ,  G01N2500/00 ,  G01N2500/04

摘要： The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of XOBESIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

摘要翻译： 本发明涉及代谢研究领域，特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症，动脉粥样硬化，胰岛素抵抗，糖尿病和高血压。 特别地，本发明提供了鉴定和使用XOBESIN活性的AGONISTS和ANTAGONISTS的方法，其中所述活性选自脂质分配，脂质代谢和胰岛素样活性。

公开(公告)号：US07326678B2

公开(公告)日：2008-02-05

申请号：US10466375

申请日：2002-01-15

申请人： Mary Ruth Erickson ,  Barbara A. Chicca ,  Bernard Bihain ,  Hiroaki Tanaka ,  Tom Chu ,  Deno P. Dialynas ,  Aaron Scalia

发明人： Mary Ruth Erickson ,  Barbara A. Chicca ,  Bernard Bihain ,  Hiroaki Tanaka ,  Tom Chu ,  Deno P. Dialynas ,  Aaron Scalia

IPC分类号： A61K38/00

CPC分类号： A61K38/1709 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/47

摘要： The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

摘要翻译： 本发明涉及代谢研究领域。 代谢紊乱，如肥胖，是一个严重而广泛的公共卫生问题。 已经鉴定出有益于治疗代谢紊乱的GMG-3，GMG-4，簇1，GMG-6A或GMG-6B多肽。 这些化合物应该有效减少体重和治疗与代谢有关的疾病和病症。 这些代谢相关的疾病和病症包括高脂血症，动脉粥样硬化，糖尿病和高血压。